Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Repligen (RGEN)

Repligen names Martin Madaus board chair effective March 13, 2026; Tony Hunt retires

Neutral Impact 3 of 5 leadership Written later

Repligen's board elected Dr. Martin D. Madaus as Chair effective March 13, 2026, succeeding Tony Hunt, who is retiring as Executive Chair and as a director on that date. Madaus has been a Repligen director since February 2023, and the board has previously determined he is independent under SEC and Nasdaq rules. The change is a leadership transition at the top of the board, and Hunt will continue as an advisor through March 2027.

Key points

  • Dr. Martin D. Madaus elected Chair of the Board, effective March 13, 2026
  • Tony Hunt, Executive Chair, retires as an employee and as a board member on March 13, 2026
  • Hunt will serve as an advisor to Repligen through March 2027
  • Madaus has been a director since February 2023 and was previously Chairman, President and CEO of Millipore Corporation

The filing

CompanyRepligen (RGEN)
Form8-K, current report
Filed with the SECJan 6, 2026, 7:32 AM ET
Accession number0001193125-26-003467

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.